Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...
If you were to point to a single device responsible for much of Hackaday’s early success, it might be the Arduino Uno. The little board from an Italian university with its easy to use dev environment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results